sábado, 22 de octubre de 2016

Neutralizing Antibodies to Severe Fever with Thrombocytopenia Syndrome Virus 4 Years after Hospitalization, China - Volume 22, Number 11—November 2016 - Emerging Infectious Disease journal - CDC

Neutralizing Antibodies to Severe Fever with Thrombocytopenia Syndrome Virus 4 Years after Hospitalization, China - Volume 22, Number 11—November 2016 - Emerging Infectious Disease journal - CDC



Volume 22, Number 11—November 2016

Dispatch

Neutralizing Antibodies to Severe Fever with Thrombocytopenia Syndrome Virus 4 Years after Hospitalization, China

Tables

Downloads

Altmetric

    Article has an altmetric score of 11
Yu-ting Huang, Li Zhao, Hong-ling Wen, Yi Yang, Hao Yu, and Xue-jie YuComments to Author 
Author affiliations: Shandong University, Jinan, China (Y.-T. Huang, L. Zhao, H.-L. Wen, Y. Yang, X.-J. Yu); Fudan University, Shanghai, China (H. Yu); University of Texas Medical Branch, Galveston, Texas, USA (X.-J. Yu)

Abstract

Severe fever with thrombocytopenia syndrome is an emerging hemorrhagic fever disease in eastern Asia, caused by a tickborne bunyavirus. Of 25 patients hospitalized with this disease in China, 100% produced and maintained neutralizing antibodies to severe fever with thrombocytopenia syndrome virus for the study period of 4 years.
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever disease in eastern Asia (1–3). SFTS is caused by SFTS virus (SFTSV), a tickborne bunyavirus that is transmitted through tick bites (1,3,4) and person to person by contact with patient blood (5,6). Clinically, SFTS is characterized by a sudden onset of fever, thrombocytopenia, hemorrhagic tendency, gastrointestinal symptoms, and multiple organ dysfunction and a high case-fatality rate of 12%–30% (1). SFTSV is a relatively new bunyavirus, and information regarding its neutralizing antibodies is scarce. In this study, we determined the prevalence and duration of neutralizing antibodies in serum samples of SFTS patients in China.

The Study

For this study, patients with a clinical diagnosis of SFTS were those who had fever, thrombocytopenia, or leukopenia without another known acute infectious disease; patients with laboratory-confirmed SFTS had SFTSV antibodies or RNA detected by ELISA or reverse transcription PCR (RT-PCR). Acute-phase (within 2 weeks after onset of illness) and convalescent-phase serum samples obtained during hospitalization of the patients were tested for total antibodies against SFTSV by using a double-antigen sandwich ELISA kit (Xinlianxin Biomedical Technology Limited, Wuxi, China). The study was approved by the ethics committee of Shandong University. Informed consent was obtained from all participants.
The ELISA plates were coated with recombinant SFTSV nucleoprotein (7). Undiluted patient serum samples were used for ELISA; SFTSV antibodies were detected with horseradish peroxidase–labeled recombinant SFTSV protein. Serum samples were considered positive for SFTSV when absorbance of the sample was >2.1 times that of a negative control at 450 nm (8). Nested RT-PCR amplification of the SFTSV RNA large segment (900 bp) and small segment (600 bp) have been described previously (8). PCR products were confirmed to be SFTSV RNA by DNA sequencing.
During June 26, 2011–August 26, 2012, a total of 46 patients were hospitalized and given a clinical diagnosis of SFTS in a local hospital in Yiyuan County, Shandong Province, China. We confirmed by ELISA or RT-PCR that 33 (71.7%) of these 46 patients were infected with SFTSV. Of the confirmed cases of SFTS, 22 occurred in 2011 and were reported previously (8). Two (6.1%) patients with confirmed SFTS died.
Among the 31 laboratory-confirmed living patients with SFTS, 25 agreed and 6 refused to donate blood samples for neutralization assay after discharge. Thirteen (52%) volunteers were male and 12 (48%) were female; their ages ranged from 42 to 75 years (median age 62 years).
Blood samples were obtained from the 25 SFTS volunteers 2 or 3 times during a 4-year period. Serum samples were heat inactivated at 56°C for 30 min and diluted in 2-fold increments from 1:5 to 1:1,280. Each dilution of serum was mixed with an equal volume of solution containing SFTSV (1,000 pfu/mL) at 37°C for 1 hour. Culture medium was used as a control for serum. Samples were tested by using the 50% plaque reduction neutralization test (PRNT50). The titer obtained is the reciprocal of the highest serum dilution that reduces the number of plaques by 50% relative to the average number of plaques in viral control wells.
At first, SFTSV does not form clear plaques on Vero cells. SFTSV is passaged on Vero cells until plaques are clearly visible. Initially, 106 SFTSV is inoculated into cells in 1 well of a 6-well plate. When a cytopathic effect is visible, cells with the cytopathic effect are aspirated with a pipette tip and transferred to a new well. A single plaque is picked and used for viral stock when the plaques are clearly visible on the fifth passage.
To determine the viral titer with a plaque assay, the viral stock is diluted from 10−2 to 10−6 in 10-fold increments. Each dilution of viral stock is used to infect 2 wells of cells. (The negative control contains maintenance medium without virus.) Infected cells are incubated at 37°C in 5% CO2 for 1 h; then, viral inoculum is replaced with Dulbecco’s modified Eagle medium containing 1.5% methylcellulose, 1% fetal bovine serum, 10 mmol/L HEPES, penicillin (100 units/mL), and streptomycin (100 µg/mL). Plates are incubated at 37°C in 5% CO2 for 10 d. The monolayer is fixed with 4% paraformaldehyde and stained with crystal violet. Plaques in each well are counted to determine the plaque-forming unit.
PRNT50 results showed that all 25 patients developed neutralizing antibodies against SFTSV at titers from 20 to 640; the neutralizing antibodies lasted for the entire study period of 4 years (Table). We also performed PRNT90 tests for all 25 patients; these showed similar results to PRNT50, but the titers were less in extent than those of PRNT50 (data not shown).
In general, the titer of neutralizing antibodies decreased over time in all but 2 patients (nos. 5 and 11), who had a higher PRNT50 titer in the last year than in the first year; this increase may have been caused by reinfection with SFTSV. However, our previous studies indicate that, in the local area, the incidence of SFTSV infection is <5 cases/100,000 population and the seroprevalence rate of SFTSV in the healthy population is <1% (8–10), suggesting that the chance of reinfection of a patient with SFTSV is low. We cannot exclude, however, that these 2 patients could have been infected with other phleboviruses that have not yet been isolated in China. Serum samples from 2 healthy persons were also tested for neutralizing antibodies as controls; neither of them had any neutralization activity against SFTSV.

Conclusions

We found that hospitalized patients with SFTS produced long-lasting neutralizing antibodies to SFTSV. We do not know the characteristics of the neutralizing antibodies against SFTSV, which need to be further investigated. In general, neutralizing antigens of bunyavirus are located on the viral glycoproteins (11–13). A neutralizing monoclonal antibody to SFTSV is found to bind a linear epitope in the ectodomain of glycoprotein Gn of SFTSV. Its neutralizing activity is attributed to blockage of the interactions between the Gn protein and the cellular receptor (14). The limitation of this study is that we obtained SFTS patients’ serum samples for only up to 4 years after diagnosis; we do not know how long the neutralizing antibodies in patients will last.
Ms. Huang is a doctoral student at Shandong University in Jinan City, China, studying the molecular epidemiology of tick-borne emerging infectious diseases.

Acknowledgment

This study was supported by grants from Shandong Province Science and Technology Development Program (no. 2014GSF121004) and National Natural Science Funds of China (nos. 31570167 and 81102171).

References

  1. Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364:1523–32.DOIPubMed
  2. Kim WY, Choi W, Park SW, Wang EB, Lee WJ, Jee Y, Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea. Clin Infect Dis. 2015;60:1681–3.DOIPubMed
  3. Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 2014;209:816–27.DOIPubMed
  4. Luo LM, Zhao L, Wen HL, Zhang ZT, Liu JW, Fang LZ, Haemaphysalis longicornis ticks as reservoir and vector of severe fever with thrombocytopenia syndrome virus in China. Emerg Infect Dis. 2015;21:1770–6.DOIPubMed
  5. Bao CJ, Guo XL, Qi X, Hu JL, Zhou MH, Varma JK, A family cluster of infections by a newly recognized bunyavirus in eastern China, 2007: further evidence of person-to-person transmission. Clin Infect Dis. 2011;53:1208–14.DOIPubMed
  6. Liu Y, Li Q, Hu W, Wu J, Wang Y, Mei L, Person-to-person transmission of severe fever with thrombocytopenia syndrome virus. Vector Borne Zoonotic Dis. 2012;12:156–60.DOIPubMed
  7. Jiao Y, Zeng X, Guo X, Qi X, Zhang X, Shi Z, Preparation and evaluation of recombinant severe fever with thrombocytopenia syndrome virus nucleocapsid protein for detection of total antibodies in human and animal sera by double-antigen sandwich enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50:372–7.DOIPubMed
  8. Wen HL, Zhao L, Zhai S, Chi Y, Cui F, Wang D, Severe fever with thrombocytopenia syndrome, Shandong Province, China, 2011. Emerg Infect Dis. 2014;20:1–5.DOIPubMed
  9. Zhao L, Zhai S, Wen H, Cui F, Chi Y, Wang L, Severe fever with thrombocytopenia syndrome virus, Shandong Province, China. Emerg Infect Dis. 2012;18:963–5.DOIPubMed
  10. Cui F, Cao HX, Wang L, Zhang SF, Ding SJ, Yu XJ, Clinical and epidemiological study on severe fever with thrombocytopenia syndrome in Yiyuan County, Shandong Province, China. Am J Trop Med Hyg. 2013;88:510–2.DOIPubMed
  11. Hofmann H, Li X, Zhang X, Liu W, Kühl A, Kaup F, Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol. 2013;87:4384–94.DOIPubMed
  12. Takenaka A, Gibbs CJ Jr, Gajdusek DC. Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch Virol. 1985;84:197–206.DOIPubMed
  13. Niklasson B, Peters CJ, Bengtsson E, Norrby E. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine. 1985;3:123–7.DOIPubMed
  14. Guo X, Zhang L, Zhang W, Chi Y, Zeng X, Li X, Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus. Clin Vaccine Immunol. 2013;20:1426–32.DOIPubMed

Table

Suggested citation for this article: Huang Y-T, Zhao L, Wen H-L, Yang Y, Yu H, Yu X-J. Neutralizing antibodies to severe fever with thrombocytopenia syndrome virus 4 years after hospitalization. Emerg Infect Dis. 2016 Nov [date cited]. http://dx.doi.org/10.3201/eid2211.160414
DOI: 10.3201/eid2211.160414


URL Validation failed because the page http://dx.doi.org/10.3201/eid2211.160414 does not exist (HTTP error 404).
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)